Biotech vets raise $67M to de­vel­op tar­get­ed ac­ti­va­tors for can­cer

Del­phia Ther­a­peu­tics said Thurs­day that it raised $67 mil­lion to de­vel­op tar­get­ed can­cer ther­a­pies that over­ac­ti­vate dri­vers of can­cer, de­fy­ing the norm es­tab­lished by decades of can­cer drug de­vel­op­ment fo­cused on in­hibit­ing those sig­nals.

The com­pa­ny was found­ed on sci­ence from Bill Sell­ers’ lab at the Broad In­sti­tute and is led by GV en­tre­pre­neur-in-res­i­dence Kevin Marks, as End­points News first re­port­ed in Sep­tem­ber. GV — Google’s ven­ture arm — is lead­ing the Se­ries A round, with Nex­tech In­vest, Po­laris In­no­va­tion Fund and Alexan­dria Ven­ture al­so in­vest­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER